Want to join the conversation?
Drug company $MRK said that they have revealed the results from the KEYNOTE-010 study of KEYTRUDA (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC). KEYNOTE-010 is a randomized, pivotal Phase 2/3 trial comparing 2 doses of KEYTRUDA (2mg/kg dose or 10mg/kg dose, each given every 3 weeks), to docetaxel, a commonly used chemotherapy.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.